BASE is an advanced facility that focuses on the production and research into synthetic DNA and RNA technologies.
The BASE facility is located in the Australian Institute of Bioengineering and Nanotechnology (AIBN) at the University of Queensland, and hosts state-of-the-art equipment and bioprocessing technologies, with a team of skilled and experienced scientists to provide leading edge nucleic-acid production capabilities.
BASE specialises in the production of high-quality nucleic-acids to support academic, clinical, industrial and agricultural research.
We provide end-to-end services, from the initial sequence design, through salable manufacture to final analytics. We support clients providing manufacturing scalable capabilities and expertise that can accelerate and translate their research.
BASE includes a team of expert scientists that leverage the unique capabilities of the facility to conduct research into novel synthetic nucleic-acid technologies, and their novel applications.
Notable research strengths include the enzymatic synthesis and sequencing of nucleic-acids, and applications in synthetic RNA and DNA in the fields of mRNA therapies, DNA stenography, synthetic biology.
Synthetic nucleic-acids are central to a range of therapies, from templates for the production of recombinant proteins and antibodies, the development of cell lines, to the direct use of nucleic acids in vaccines.
BASE, in partnership with TIA, PEF and NBF, supports the production and use of synthetic nucleic-acids for translational use, including pre-clinical and early clinical leads.
BASE facility works closely with industrial and agricultural partners to develop synthetic nucleic-acids for commercial applications. This includes the use of nucleic-acids in pest control, veterinary vaccines, and crop science.
BASE supports commercial partners, ranging from early-stage start-ups to large multinational companies, in developing prototypes and products according to their specific needs.